An immunomodulatory molecular analogue of thalidomide, which has shown promise in phase 2 studies for managing myeloma, and possibly other cancers.
Adverse effects BM suppression with anaemia, thrombocytopaenia, neutropaenia, diarrhoea, fever, muscle cramps, neuropathy, constipation, rash, fatigue.
References in periodicals archive ?
James Evans, a pharmaceutical industry analyst in visiongain, said: “The years 2012 to 2013 will see two important new products reach the market, Onyx's Kyprolis and Celgene's Actimid.